The Standard of Care: Your Medication Foundation

When you are diagnosed with heart failure, your medical team will prescribe a specific combination of medications known as Guideline-Directed Medical Therapy (GDMT). These are “disease-modifying” treatments proven to help the heart function more effectively, reduce hospitalizations, and improve survival ^[1][2].

The Four Pillars of HFrEF Treatment

For patients with Heart Failure with Reduced Ejection Fraction (HFrEF), the standard of care is built on four core “pillars.” Using them together provides the greatest protection ^[3][1].

1. ARNI, ACEi, or ARB: These medications relax your blood vessels and lower the workload on your heart ^[2][4]. Examples include sacubitril/valsartan, lisinopril, or losartan. Safety Warning: Take ONLY ONE of these classes as prescribed. They should never be combined, and switching to sacubitril/valsartan from an ACE inhibitor requires a specific washout period to prevent severe reactions.
2. Beta-blockers: Medications like metoprolol succinate, carvedilol, or bisoprolol protect the heart muscle from stress hormones and control heart rate ^[2].
3. MRAs (Mineralocorticoid Receptor Antagonists): Medications like spironolactone or eplerenone block hormones that cause the heart to stiffen or scar ^[2][4].
4. SGLT2 Inhibitors: Originally used for diabetes, drugs like dapagliflozin or empagliflozin significantly reduce heart failure events, even in people without diabetes ^[1][5].

A Modern Approach to Starting Medications

In the past, doctors often started one medication and waited months before adding another. Today, the goal is often early initiation—starting low doses of multiple classes as soon as safely possible, often during or shortly after a hospital stay ^[6][7].

However, this is not a rigid deadline. Your doctor will individualize your timeline based on your blood pressure, kidney function, and potassium levels ^[6]. For example, beta-blockers are generally only started or increased when you are clinically stable and not severely congested. Do not adjust these doses yourself; report any symptoms like dizziness or fatigue to your team so they can safely titrate (adjust) the plan ^[8].

Treatment for Other Subtypes (HFpEF and HFmrEF)

If your ejection fraction is “preserved” or “mildly reduced,” your treatment plan will look different. SGLT2 inhibitors currently have the strongest evidence for reducing heart failure hospitalizations across the entire spectrum of heart function ^[9][10][11].

However, management goes beyond a single drug. Treatment also heavily involves relieving congestion with diuretics, and aggressively managing contributing factors like high blood pressure, atrial fibrillation, diabetes, obesity, and sleep apnea.

Disease-Modifying vs. Symptom-Relief Drugs

It is important to distinguish between the medications that protect the heart long-term and those that manage immediate symptoms:

• Disease-Modifying Therapy (The Four Pillars): These are your “long-term” drugs for HFrEF. You must take them consistently, even if you don’t feel an immediate difference in energy ^[1].
• Symptom-Relief (Loop Diuretics): Often called “water pills” (like furosemide or bumetanide), these relieve breathlessness and swelling by removing extra fluid from your body ^[4]. They are vital for comfort but do not reverse the underlying heart condition ^[12].

When Medication Isn’t Enough: Device Therapy

If your ejection fraction remains at 35% or lower after you have been on optimized medical therapy for 3 to 6 months, this may prompt your doctor to evaluate you for specialized devices ^[13][14]:

• ICD (Implantable Cardioverter Defibrillator): A device that monitors your rhythm and can provide a life-saving “shock” if it detects a dangerous, fast heartbeat ^[13].
• CRT (Cardiac Resynchronization Therapy): Also called a biventricular pacemaker, this device helps the left and right sides of your heart beat in sync. It is most effective for patients who have a specific electrical delay (often seen as a “wide QRS” on an EKG) ^[15][16].

An EF of 35% or less does not automatically guarantee eligibility. Device decisions also depend on your heart rhythm, expected survival, other medical conditions, and symptoms ^[14].